What is Tesamorelin and how does it differ from native GHRH in GH release dynamics?

Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH) comprising the active 44 amino acid sequence of GHRH with an added trans-3-hexenoic acid group (hexenoyl modification) at the N-terminus. This lipid modification dramatically extends half-life vs native GHRH which degrades within minutes via dipeptidyl peptidase-IV (DPP-IV) cleavage and rapid renal clearance. Native GHRH has half-life <10 minutes; Tesamorelin's hexenoyl group provides steric hindrance protecting against DPP-IV enzymatic degradation extending half-life to 30-50 minutes enabling sustained GHRH receptor (GHRHR) activation in anterior pituitary somatotrophs. Mechanistically both bind GHRHR (G-protein coupled receptor) triggering adenylyl cyclase-cAMP-PKA pathway and Ca2+ mobilization stimulating growth hormone secretion, but Tesamorelin's extended bioavailability produces prolonged pulsatile GH release. Research applications include GHRH receptor pharmacology, pituitary somatotroph biology, GH secretion dynamics, hypothalamic-pituitary-IGF-1 axis studies, and lipid metabolism regulation - particularly visceral adipose tissue reduction mechanisms since Tesamorelin demonstrates preferential mobilization of intra-abdominal fat through GH-stimulated lipolysis.

How does Tesamorelin stimulate GH secretion and what downstream metabolic effects result?

Tesamorelin binds growth hormone-releasing hormone receptors (GHRHR) on anterior pituitary somatotroph cells triggering Gs-protein-mediated adenylyl cyclase activation producing cAMP second messenger accumulation. Elevated cAMP activates protein kinase A (PKA) which phosphorylates transcription factors (CREB) promoting GH gene transcription and stimulates voltage-gated calcium channels increasing intracellular Ca2+ triggering GH vesicle exocytosis. This dual mechanism (gene transcription + vesicle release) produces biphasic GH secretion: rapid release (minutes) from pre-formed GH granules followed by sustained secretion (hours) from de novo GH synthesis. Released GH circulates to liver and peripheral tissues binding growth hormone receptors (GHR) stimulating JAK2-STAT5 signaling and insulin-like growth factor-1 (IGF-1) production - the primary mediator of GH's anabolic/metabolic effects. GH and IGF-1 promote: lipolysis in adipocytes (particularly visceral fat) via hormone-sensitive lipase activation releasing free fatty acids for oxidation, protein synthesis in skeletal muscle through PI3K-AKT-mTOR pathway activation, hepatic glucose production via gluconeogenesis, and nitrogen retention. Tesamorelin research enables investigating GHRH-GH-IGF-1 axis regulation, visceral adiposity mechanisms, lipid metabolism pathways, and metabolic effects of pulsatile vs continuous GH exposure.

What purity and quality standards does your Tesamorelin meet for research?

Our Tesamorelin exceeds >98% purity verified by reverse-phase HPLC demonstrating retention time characteristic of the 44-amino acid GHRH sequence with N-terminal hexenoyl lipid modification. Each batch undergoes comprehensive quality control: mass spectrometry confirmation of molecular weight (~5135 Da including hexenoyl group vs ~5040 Da for unmodified GHRH) validating trans-3-hexenoic acid conjugation, peptide sequencing via Edman degradation or MS/MS fragmentation verifying the complete 44-AA GHRH sequence plus hexenoyl attachment at N-terminus, GHRH receptor binding bioassays using pituitary cells or GHRHR-expressing cell lines measuring Tesamorelin's affinity (typically nanomolar Kd) and demonstrating competitive displacement of radiolabeled GHRH, functional GH secretion assays treating primary pituitary somatotroph cultures or GH3 cells with Tesamorelin measuring dose-dependent GH release via ELISA or luminescence immunoassay quantifying EC50 potency, cAMP accumulation assays confirming GHRHR-Gs-adenylyl cyclase pathway activation via cAMP ELISA or bioluminescence resonance energy transfer (BRET) biosensors, DPP-IV resistance testing comparing Tesamorelin vs native GHRH degradation kinetics in presence of dipeptidyl peptidase-IV enzyme demonstrating hexenoyl modification provides proteolytic protection, endotoxin testing (<0.1 EU/mg), and comprehensive Certificate of Analysis with batch number and manufacturing date.

What research applications benefit from Tesamorelin's extended GHRH activity?

Tesamorelin excels in research requiring sustained GHRH receptor stimulation: pituitary somatotroph biology investigating GHRHR signaling (Gs-cAMP-PKA, Ca2+ mobilization), GH gene regulation, secretory granule dynamics, and desensitization mechanisms from prolonged vs pulsatile GHRHR activation; GH secretion dynamics studying pulsatile GH release patterns, feedback regulation by somatostatin and IGF-1, age-related GH decline mechanisms, and hypothalamic-pituitary axis integration; visceral adiposity research as Tesamorelin demonstrates preferential reduction of intra-abdominal fat - investigating GH-mediated lipolysis in visceral vs subcutaneous adipocytes, hormone-sensitive lipase activation, perilipin phosphorylation, free fatty acid mobilization, and adipocyte apoptosis/remodeling pathways; lipid metabolism studies examining GH effects on triglyceride hydrolysis, fatty acid oxidation (beta-oxidation enzymes), hepatic lipogenesis, and lipoprotein metabolism; metabolic syndrome models investigating how GH elevation affects insulin sensitivity (GH's diabetogenic effects via insulin receptor substrate-1 serine phosphorylation vs IGF-1's insulin-sensitizing actions), glucose homeostasis, and cardiovascular risk markers; HIV-associated lipodystrophy research where Tesamorelin has shown efficacy reducing visceral adipose tissue; comparative GHRH analog studies evaluating Tesamorelin vs sermorelin vs CJC-1295 for half-life, potency, and metabolic effects; pharmaceutical development of GHRH-based therapeutics for growth disorders or metabolic conditions; and aging research investigating GH/IGF-1 axis restoration strategies.

How should Tesamorelin be stored and reconstituted for research protocols?

Store lyophilized Tesamorelin at -20°C in original sealed vials for 24+ months stability. The lyophilized formulation with hexenoyl modification remains stable when dry and frozen - protect from moisture and light (amber vials recommended as peptides can photodegrade). Reconstitute using sterile water, bacteriostatic water (0.9% benzyl alcohol), or dilute acetic acid solution slowly down vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 1-5 mg/mL. Allow 2-3 minutes for complete dissolution. Refrigerate reconstituted solution at 2-8°C and use within 14 days for maximum bioactivity - GHRH analogs in aqueous solution degrade via oxidation, deamidation, and aggregation over time. For optimal stability reconstitute in slightly acidic pH (0.1M acetic acid or pH 5-6 buffer) as GHRH peptides are most stable at mildly acidic conditions. Avoid multiple freeze-thaw cycles which cause peptide aggregation and loss of GHRHR binding activity - for multi-week protocols aliquot reconstituted solution into single-use sterile vials immediately after reconstitution storing aliquots at -20°C. Thaw fresh aliquot for each experiment accepting one freeze-thaw cycle. Light protection critical: store in amber vials or aluminum foil wrap. Prior to cell culture or functional assays allow solution to reach room temperature and verify pH compatibility with experimental system.

Why does Tesamorelin preferentially reduce visceral adipose tissue vs subcutaneous fat?

Tesamorelin-stimulated GH release produces preferential visceral fat reduction through multiple mechanisms: (1) Visceral adipocytes express higher density of GH receptors (GHR) and beta-adrenergic receptors than subcutaneous adipocytes making them more responsive to GH-stimulated lipolysis. (2) GH binding to adipocyte GHR activates JAK2-STAT5 pathway inducing hormone-sensitive lipase (HSL) gene expression and phosphorylating HSL/perilipin proteins triggering triglyceride hydrolysis releasing free fatty acids. (3) Visceral adipose tissue has greater blood flow and innervation facilitating GH delivery and sympathetic nervous system-mediated lipolysis amplification. (4) GH reduces lipoprotein lipase (LPL) activity in adipocytes decreasing triglyceride uptake/storage while increasing adipose triglyceride lipase (ATGL) expression promoting fat mobilization - these effects are more pronounced in visceral depots. (5) IGF-1 produced in response to GH may modulate adipocyte differentiation and survival with depot-specific effects. (6) Visceral adipocytes show reduced insulin sensitivity compared to subcutaneous fat; GH's lipolytic actions overcome insulin's anti-lipolytic effects more readily in visceral depots. (7) Chronic GH elevation may promote visceral adipocyte apoptosis via oxidative stress or metabolic stress pathways. Research applications include visceral obesity mechanisms, adipocyte biology across fat depots, GH receptor signaling in metabolic tissues, and therapeutic strategies for reducing ectopic fat accumulation associated with metabolic syndrome.

What dosage specifications and bulk pricing are available for Tesamorelin research?

We offer three Tesamorelin specifications: TSM2 (2mg per 10-vial kit), TSM5 (5mg per 10-vial kit), TSM10 (10mg per 10-vial kit). Pricing with bulk discounts: TSM2: $100/kit (1 kit), $95/kit (20+ kits = 5% discount), $90/kit (50+ kits = 10% discount). TSM5: $150/kit (1 kit), $145/kit (20+ kits = 3.3% discount), $140/kit (50+ kits = 6.7% discount). TSM10: $230/kit (1 kit), $220/kit (20+ kits = 4.3% discount), $210/kit (50+ kits = 8.7% discount). The three concentration options accommodate diverse research from pilot GHRHR binding and GH secretion dose-response characterization (lower concentrations for in vitro screening) to extensive visceral adiposity studies and chronic GH axis modulation protocols (higher concentrations for extended metabolic research). Pricing reflects synthesis complexity of the 44-amino acid GHRH sequence with N-terminal hexenoyl lipid modification requiring stereospecific trans-3-hexenoic acid conjugation, rigorous quality control (HPLC purity, mass spec confirming hexenoyl attachment, GHRHR binding assays, GH secretion bioassays, DPP-IV resistance validation, cAMP signaling confirmation), and comprehensive CoA documentation while maintaining >98% purity essential for reproducible GHRH pharmacology and metabolic research. Bulk discounts support institutional pituitary biology core facilities, multi-year visceral adiposity research programs, pharmaceutical GHRH analog development, comparative growth factor studies, and international metabolic research consortia. Contact via WhatsApp to discuss custom quantities for large-scale projects.

How do you validate Tesamorelin's GHRH receptor activation and GH secretory function?

Beyond chemical purity (HPLC >98%, mass spec confirming hexenoyl-modified 44-AA structure), we employ comprehensive receptor binding and functional bioassays: (1) GHRH receptor binding assays using anterior pituitary cells, GH3 rat pituitary tumor cells, or GHRHR-transfected cell lines measuring Tesamorelin's ability to compete with radiolabeled GHRH for receptor binding (competition binding determining IC50) or directly bind GHRHR (saturation binding determining Kd affinity typically 1-10 nM) demonstrating high-affinity receptor recognition. (2) GH secretion bioassays - the gold standard functional validation: treating primary pituitary somatotroph cultures or GH3 cells with dose-escalating Tesamorelin measuring GH release into media via ELISA, chemiluminescence, or radioimmunoassay quantifying EC50 potency (typically nanomolar range) and maximum GH secretion demonstrating functional GHRHR activation translates to hormone release. (3) cAMP accumulation assays measuring second messenger production - treating GHRHR-expressing cells with Tesamorelin and quantifying intracellular cAMP via ELISA, bioluminescence (GloSensor), or BRET biosensors confirming Gs-protein-adenylyl cyclase pathway activation dose-dependently. (4) PKA activation assays measuring protein kinase A activity via phosphorylation of downstream substrates (phospho-CREB Western blot) or FRET-based PKA biosensors demonstrating cAMP signal transduction. (5) Calcium mobilization assays using fluorescent Ca2+ indicators (Fluo-4, Fura-2) measuring intracellular calcium elevations upon Tesamorelin treatment validating ion channel activation component of GHRHR signaling. (6) DPP-IV resistance testing - incubating Tesamorelin vs native GHRH with purified dipeptidyl peptidase-IV enzyme and measuring peptide degradation over time via HPLC/mass spec demonstrating hexenoyl modification provides proteolytic protection extending half-life.

Can Tesamorelin be combined with other compounds for synergistic GH research?

Yes! Tesamorelin combinations enable investigating multi-factorial GH regulation: (1) Tesamorelin + GHRP-6/Ipamorelin (GH secretagogues) - GHRH analogs and GHRPs act through different receptors (GHRHR vs ghrelin receptor) producing synergistic GH release exceeding additive effects from either alone. This combination reveals receptor crosstalk and demonstrates how hypothalamic GHRH and peripheral ghrelin signals integrate at pituitary somatotrophs. (2) Tesamorelin + somatostatin/octreotide - somatostatin inhibits GH release via SSTR2/SSTR5 receptors; co-treatment investigates GHRH-somatostatin balance, pulsatile GH secretion regulation, and receptor desensitization mechanisms. (3) Tesamorelin + IGF-1 - exogenous IGF-1 normally suppresses GH via negative feedback; combined treatment dissects direct GH effects from IGF-1-mediated effects and investigates feedback loop dynamics. (4) Tesamorelin + thyroid hormone (T3) - thyroid hormones potentiate GH signaling and IGF-1 production; combination studies reveal permissive hormonal interactions. (5) Tesamorelin + insulin/metformin - investigating interactions between GH (diabetogenic) and insulin-sensitizing agents in glucose metabolism research. (6) Tesamorelin + testosterone - both anabolic hormones acting through different pathways (GHR/IGF-1R vs androgen receptor); synergistic muscle/metabolic effects from independent mechanisms. (7) Tesamorelin + exercise/fasting protocols - physiological GH stimuli combined with pharmacological GHRH activation modeling enhanced metabolic states. Research benefits include understanding multi-hormonal regulation, optimizing GH secretion protocols, and dissecting complex metabolic pathway interactions.

What documentation and international shipping support Tesamorelin metabolic research?

We ship Tesamorelin in lyophilized form with cold pack insulation in sealed packaging protecting the hexenoyl-modified GHRH analog. Lyophilized peptide remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation. International delivery typically takes 10-14 days with tracking; immediately transfer to -20°C storage upon arrival. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time characteristic of hexenoyl-GHRH (longer retention than unmodified GHRH due to lipid modification), mass spectrometry data confirming molecular weight (~5135 Da) validating trans-3-hexenoic acid conjugation at N-terminus vs unmodified 44-AA GHRH (~5040 Da), peptide sequence verification via Edman degradation or tandem mass spec confirming complete GHRH sequence plus hexenoyl attachment point, GHRH receptor binding assay results showing competitive displacement of native GHRH with IC50 or Kd quantification (typically 1-10 nM), GH secretion bioassay dose-response data using primary pituitary cells or GH3 cells with EC50 values for GH release (nanomolar potency range), cAMP accumulation assay confirming GHRHR-Gs-adenylyl cyclase signaling activation, DPP-IV resistance data comparing Tesamorelin vs native GHRH degradation kinetics demonstrating hexenoyl protection extends half-life, endotoxin testing (<0.1 EU/mg), batch number and manufacturing date. This documentation satisfies institutional biosafety committees and regulatory requirements worldwide ensuring compliance for pituitary biology research, metabolic investigations, and GHRH pharmacology studies across global research institutions.

Home ProductsTesamorelin

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

TES2

Tesamorelin

Q: How does Tesamorelin stimulate GH secretion and what downstream metabolic effects result?

Tesamorelin binds growth hormone-releasing hormone receptors (GHRHR) on anterior pituitary somatotroph cells triggering Gs-protein-mediated adenylyl cyclase activation producing cAMP second messenger accumulation. Elevated cAMP activates protein kinase A (PKA) which phosphorylates transcription factors (CREB) promoting GH gene transcription and stimulates voltage-gated calcium channels increasing intracellular Ca2+ triggering GH vesicle exocytosis. This dual mechanism (gene transcription + vesicle release) produces biphasic GH secretion: rapid release (minutes) from pre-formed GH granules followed by sustained secretion (hours) from de novo GH synthesis. Released GH circulates to liver and peripheral tissues binding growth hormone receptors (GHR) stimulating JAK2-STAT5 signaling and insulin-like growth factor-1 (IGF-1) production - the primary mediator of GH's anabolic/metabolic effects. GH and IGF-1 promote: lipolysis in adipocytes (particularly visceral fat) via hormone-sensitive lipase activation releasing free fatty acids for oxidation, protein synthesis in skeletal muscle through PI3K-AKT-mTOR pathway activation, hepatic glucose production via gluconeogenesis, and nitrogen retention. Tesamorelin research enables investigating GHRH-GH-IGF-1 axis regulation, visceral adiposity mechanisms, lipid metabolism pathways, and metabolic effects of pulsatile vs continuous GH exposure.

Q: What purity and quality standards does your Tesamorelin meet for research?

Our Tesamorelin exceeds >98% purity verified by reverse-phase HPLC demonstrating retention time characteristic of the 44-amino acid GHRH sequence with N-terminal hexenoyl lipid modification. Each batch undergoes comprehensive quality control: mass spectrometry confirmation of molecular weight (~5135 Da including hexenoyl group vs ~5040 Da for unmodified GHRH) validating trans-3-hexenoic acid conjugation, peptide sequencing via Edman degradation or MS/MS fragmentation verifying the complete 44-AA GHRH sequence plus hexenoyl attachment at N-terminus, GHRH receptor binding bioassays using pituitary cells or GHRHR-expressing cell lines measuring Tesamorelin's affinity (typically nanomolar Kd) and demonstrating competitive displacement of radiolabeled GHRH, functional GH secretion assays treating primary pituitary somatotroph cultures or GH3 cells with Tesamorelin measuring dose-dependent GH release via ELISA or luminescence immunoassay quantifying EC50 potency, cAMP accumulation assays confirming GHRHR-Gs-adenylyl cyclase pathway activation via cAMP ELISA or bioluminescence resonance energy transfer (BRET) biosensors, DPP-IV resistance testing comparing Tesamorelin vs native GHRH degradation kinetics in presence of dipeptidyl peptidase-IV enzyme demonstrating hexenoyl modification provides proteolytic protection, endotoxin testing (<0.1 EU/mg), and comprehensive Certificate of Analysis with batch number and manufacturing date.

Q: What research applications benefit from Tesamorelin's extended GHRH activity?

Tesamorelin excels in research requiring sustained GHRH receptor stimulation: pituitary somatotroph biology investigating GHRHR signaling (Gs-cAMP-PKA, Ca2+ mobilization), GH gene regulation, secretory granule dynamics, and desensitization mechanisms from prolonged vs pulsatile GHRHR activation; GH secretion dynamics studying pulsatile GH release patterns, feedback regulation by somatostatin and IGF-1, age-related GH decline mechanisms, and hypothalamic-pituitary axis integration; visceral adiposity research as Tesamorelin demonstrates preferential reduction of intra-abdominal fat - investigating GH-mediated lipolysis in visceral vs subcutaneous adipocytes, hormone-sensitive lipase activation, perilipin phosphorylation, free fatty acid mobilization, and adipocyte apoptosis/remodeling pathways; lipid metabolism studies examining GH effects on triglyceride hydrolysis, fatty acid oxidation (beta-oxidation enzymes), hepatic lipogenesis, and lipoprotein metabolism; metabolic syndrome models investigating how GH elevation affects insulin sensitivity (GH's diabetogenic effects via insulin receptor substrate-1 serine phosphorylation vs IGF-1's insulin-sensitizing actions), glucose homeostasis, and cardiovascular risk markers; HIV-associated lipodystrophy research where Tesamorelin has shown efficacy reducing visceral adipose tissue; comparative GHRH analog studies evaluating Tesamorelin vs sermorelin vs CJC-1295 for half-life, potency, and metabolic effects; pharmaceutical development of GHRH-based therapeutics for growth disorders or metabolic conditions; and aging research investigating GH/IGF-1 axis restoration strategies.

Q: How should Tesamorelin be stored and reconstituted for research protocols?

Store lyophilized Tesamorelin at -20°C in original sealed vials for 24+ months stability. The lyophilized formulation with hexenoyl modification remains stable when dry and frozen - protect from moisture and light (amber vials recommended as peptides can photodegrade). Reconstitute using sterile water, bacteriostatic water (0.9% benzyl alcohol), or dilute acetic acid solution slowly down vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 1-5 mg/mL. Allow 2-3 minutes for complete dissolution. Refrigerate reconstituted solution at 2-8°C and use within 14 days for maximum bioactivity - GHRH analogs in aqueous solution degrade via oxidation, deamidation, and aggregation over time. For optimal stability reconstitute in slightly acidic pH (0.1M acetic acid or pH 5-6 buffer) as GHRH peptides are most stable at mildly acidic conditions. Avoid multiple freeze-thaw cycles which cause peptide aggregation and loss of GHRHR binding activity - for multi-week protocols aliquot reconstituted solution into single-use sterile vials immediately after reconstitution storing aliquots at -20°C. Thaw fresh aliquot for each experiment accepting one freeze-thaw cycle. Light protection critical: store in amber vials or aluminum foil wrap. Prior to cell culture or functional assays allow solution to reach room temperature and verify pH compatibility with experimental system.

Q: Why does Tesamorelin preferentially reduce visceral adipose tissue vs subcutaneous fat?

Tesamorelin-stimulated GH release produces preferential visceral fat reduction through multiple mechanisms: (1) Visceral adipocytes express higher density of GH receptors (GHR) and beta-adrenergic receptors than subcutaneous adipocytes making them more responsive to GH-stimulated lipolysis. (2) GH binding to adipocyte GHR activates JAK2-STAT5 pathway inducing hormone-sensitive lipase (HSL) gene expression and phosphorylating HSL/perilipin proteins triggering triglyceride hydrolysis releasing free fatty acids. (3) Visceral adipose tissue has greater blood flow and innervation facilitating GH delivery and sympathetic nervous system-mediated lipolysis amplification. (4) GH reduces lipoprotein lipase (LPL) activity in adipocytes decreasing triglyceride uptake/storage while increasing adipose triglyceride lipase (ATGL) expression promoting fat mobilization - these effects are more pronounced in visceral depots. (5) IGF-1 produced in response to GH may modulate adipocyte differentiation and survival with depot-specific effects. (6) Visceral adipocytes show reduced insulin sensitivity compared to subcutaneous fat; GH's lipolytic actions overcome insulin's anti-lipolytic effects more readily in visceral depots. (7) Chronic GH elevation may promote visceral adipocyte apoptosis via oxidative stress or metabolic stress pathways. Research applications include visceral obesity mechanisms, adipocyte biology across fat depots, GH receptor signaling in metabolic tissues, and therapeutic strategies for reducing ectopic fat accumulation associated with metabolic syndrome.

Q: What dosage specifications and bulk pricing are available for Tesamorelin research?

We offer three Tesamorelin specifications: TSM2 (2mg per 10-vial kit), TSM5 (5mg per 10-vial kit), TSM10 (10mg per 10-vial kit). Pricing with bulk discounts: TSM2: $100/kit (1 kit), $95/kit (20+ kits = 5% discount), $90/kit (50+ kits = 10% discount). TSM5: $150/kit (1 kit), $145/kit (20+ kits = 3.3% discount), $140/kit (50+ kits = 6.7% discount). TSM10: $230/kit (1 kit), $220/kit (20+ kits = 4.3% discount), $210/kit (50+ kits = 8.7% discount). The three concentration options accommodate diverse research from pilot GHRHR binding and GH secretion dose-response characterization (lower concentrations for in vitro screening) to extensive visceral adiposity studies and chronic GH axis modulation protocols (higher concentrations for extended metabolic research). Pricing reflects synthesis complexity of the 44-amino acid GHRH sequence with N-terminal hexenoyl lipid modification requiring stereospecific trans-3-hexenoic acid conjugation, rigorous quality control (HPLC purity, mass spec confirming hexenoyl attachment, GHRHR binding assays, GH secretion bioassays, DPP-IV resistance validation, cAMP signaling confirmation), and comprehensive CoA documentation while maintaining >98% purity essential for reproducible GHRH pharmacology and metabolic research. Bulk discounts support institutional pituitary biology core facilities, multi-year visceral adiposity research programs, pharmaceutical GHRH analog development, comparative growth factor studies, and international metabolic research consortia. Contact via WhatsApp to discuss custom quantities for large-scale projects.

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade Tesamorelin for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $205/kit

+$190

extra savings

Total Price

$300

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.15% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

Tesamorelin: Key Facts

Tesamorelin is a fat loss research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 3 formats starting at $300 per kit. Each batch is independently HPLC-verified at 99.15% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	Tesamorelin
Research category	Fat Loss
Available formats	2mg10vials, 5mg10vials, 10mg*10vials
Starting price	From $300 USD per kit
Purity	99.15% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Priya Menon

Poland

"Our endocrinology research lab at a pharmaceutical research facility has been using LyzeLabs Tesamorelin for GHRH receptor signaling studies for 9 months with outstanding pharmaceutical quality. We independently verified >98.6% purity via HPLC and mass spectrometry confirmed the hexenoyl-modified 44-amino acid structure (molecular weight 5136 Da matching theoretical for trans-3-hexenoic acid conjugation). Our research investigates Tesamorelin's extended bioavailability vs native GHRH - primary rat pituitary cell GH secretion assays show robust dose-dependent release with EC50 ~2.1 nM and sustained secretion over 4-6 hour timecourse vs native GHRH's rapid decline within 30 minutes from DPP-IV degradation. We validated proteolytic resistance by incubating with purified DPP-IV enzyme - HPLC analysis shows Tesamorelin remains >90% intact after 2 hours while native GHRH degrades completely within 15 minutes, confirming the hexenoyl modification provides enzymatic protection. cAMP accumulation assays in GHRHR-expressing cells demonstrate potent adenylyl cyclase activation. The TSM5 specification supports our dose-titration protocols perfectly. Delivery to Berlin takes 11-13 days with cold-chain packaging. Premier GHRH analog for metabolic research internationally."

2025-11-16

Zoe T.

United States

"Been buying for a few months. The COA-to-lot match is consistent, order to order."

2025-11-13

Ravi K.

Sweden

"Their lab-results page made verification quick. Batch matched the vial."

2025-11-10

About This Product

Tesamorelin Research Guide

The Visceral Fat Targeted GHRH Analog

Tesamorelin is a synthetic GHRH (growth hormone releasing hormone) analog with an N-terminal trans-3-hexenoic acid modification that stabilizes it against enzymatic degradation and extends its functional half-life relative to native GHRH. Structurally it is a 44 amino acid peptide closely related to the other GHRH analogs in the LyzeLabs catalog.

Where Tesamorelin differs in research positioning is its documented effect on visceral adipose tissue specifically. Clinical research programs established Tesamorelin as a compound with particularly strong signal in reducing visceral fat accumulation in studied populations, which is why it is a distinct research tool rather than simply another GHRH analog.

Mechanism

GHRH receptor activation: binds the GHRH receptor on pituitary somatotroph cells and triggers growth hormone release via the cAMP pathway
Physiologic GH pulse profile: produces endogenous GH release rather than supplying exogenous GH, preserving natural pulsatile dynamics
Visceral fat specificity: research models and clinical trials consistently show preferential effects on visceral (rather than subcutaneous) adipose depots
Downstream IGF-1 axis engagement: drives hepatic IGF-1 production through the restored GH pulse

Research Applications

Visceral adipose tissue research, particularly NAFLD-adjacent and metabolic syndrome models
GHRH receptor pharmacology with specific focus on visceral versus subcutaneous fat responses
HIV-associated lipodystrophy research, which is the primary clinical research lineage for Tesamorelin
Comparative research against other GHRH analogs including [Sermorelin](/product/sermorelin-acetate) and [CJC-1295](/product/cjc-1295-with-dac)
Metabolic research where the GH axis is the intervention and visceral fat is the outcome measure

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Form: lyophilized powder in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For research purposes only. Not for human consumption or therapeutic use.

Research Context for Tesamorelin

Lipolysis and Fat Metabolism Research Context

Fat metabolism research peptides target lipolysis, mitochondrial fatty acid oxidation, brown adipose activation, or direct effects on adipocyte viability. Research protocols measure body composition, lipid panel markers, and tissue-specific fat mobilization under defined experimental conditions.

Tesamorelin ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Fat Loss category, with 3 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Fat Loss Category

Research Tools for This Compound

Frequently Asked Questions

Tesamorelin

$300